7-fluoropyrido[3,2-b]pyrazin-3(4H)-one | 1003944-83-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶吡嗪类
• 英文名称: 7-fluoropyrido[3,2-b]pyrazin-3(4H)-one
• 英文别名: 7-Fluoropyrido[2,3-b]pyrazin-3(4h)-one；7-fluoro-4H-pyrido[2,3-b]pyrazin-3-one
• CAS: 1003944-83-9
• 化学式: C₇H₄FN₃O
• 分子量: 165.127
• InChiKey: SQGMMXVXYWYUKJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,3-二氨基-5-氟吡啶 、 乙醛酸 以 乙醇 为溶剂， 反应 12.0h， 生成 7-fluoropyrido[3,2-b]pyrazin-3(4H)-one 、 7-fluoropyrido(2,3-b)pyrazin-2(1H)-one
  参考文献：
  名称：

  具有改善的hERG和抗结核分枝杆菌的体内功效的新型基于N-联氨基氨基哌啶的促旋酶抑制剂

  摘要：

  DNA促旋酶是开发抗结核分枝杆菌药物的临床验证靶标（MTB）。尽管有希望将氟喹诺酮类药物（FQs）用作抗结核药物，但先前对FQs耐药的流行很可能会限制其临床价值。我们描述了一种新型的N-连接的氨基哌啶基烷基喹诺酮类和萘啶酮类，通过抑制DNA促旋酶活性杀死Mtb。DNA促旋酶的抑制机制与氟喹诺酮类截然不同，其抑制氟喹诺酮类抗性Mtb生长的能力证明了这一点。生化研究表明，该类化合物通过单链裂解而不是双链裂解发挥作用，如氟喹诺酮类药物所见。这些化合物对细胞外和细胞内的Mtb具有高度的杀菌作用。铅的优化导致鉴定了具有改善的口服生物利用度并降低了心脏离子通道负担的有效化合物。该系列化合物在各种结核病鼠模型中均有效。

  DOI：

  10.1021/jm500432n

文献信息

• DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES
  申请人：Ballell Llius

  公开号：US20090270374A1

  公开（公告）日：2009-10-29

  Bicyclic nitrogen containing compounds and their use as antibacterials.

  双环氮含有化合物及其作为抗菌剂的应用。
• Benzimidazoles: Novel Mycobacterial Gyrase Inhibitors from Scaffold Morphing
  作者：Shahul Hameed P、Anandkumar Raichurkar、Prashanti Madhavapeddi、Sreenivasaiah Menasinakai、Sreevalli Sharma、Parvinder Kaur、Radha Nandishaiah、Vijender Panduga、Jitendar Reddy、Vasan K. Sambandamurthy、D. Sriram

  DOI：10.1021/ml5001728

  日期：2014.7.10

  Type II topoisomerases are well conserved across the bacterial species, and inhibition of DNA gyrase by fluoroquinolones has provided an attractive option for treatment of tuberculosis (TB). However, the emergence of fluoroquinolone-resistant strains of Mycobacterium tuberculosis (Mtb) poses a threat for its sustainability. A scaffold hopping approach using the binding mode of novel bacterial topoisomerase inhibitors (NBTIs) led to the identification of a novel class of benzimidazoles as DNA gyrase inhibitors with potent anti-TB activity. Docking of benzimidazoles to a NBTI bound crystal structure suggested that this class of compound makes key contacts in the enzyme active site similar to the reported NBTIs. This observation was further confirmed through the measurement of DNA gyrase inhibition, and activity against Mtb strains harboring mutations that confer resistance to aminopiperidines based NBTIs and Mtb strains resistant to moxifloxacin. Structure activity relationship modification at the C-7 position of the left-hand side ring provided further avenue to improve hERG selectivity for this chemical series that has been the major challenges for NBTIs.
• EP1992628A1
  申请人：——

  公开号：EP1992628A1

  公开（公告）日：2008-11-19
• US8071592B2
  申请人：——

  公开号：US8071592B2

  公开（公告）日：2011-12-06